about
An ETP model (exclusion-tolerance-progression) for multi drug resistanceTheory and Experimental Validation of a Spatio-temporal Model of Chemotherapy Transport to Enhance Tumor Cell KillBEMER Electromagnetic Field Therapy Reduces Cancer Cell Radioresistance by Enhanced ROS Formation and Induced DNA DamageDormancy of cancer cells with suppression of AKT activity contributes to survival in chronic hypoxia.Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments.Atypical cell populations associated with acquired resistance to cytostatics and cancer stem cell features: the role of mitochondria in nuclear encapsulationUnderstanding Drug Resistance in Breast Cancer with Mathematical OncologyImproved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiationA multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics.Three-dimensional multispecies nonlinear tumor growth-II: Tumor invasion and angiogenesisFTIR spectroscopy demonstrates biochemical differences in mammalian cell cultures at different growth stagesRaman spectroscopy detects biochemical changes due to proliferation in mammalian cell culturesAre cancer stem cells radioresistant?Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxiaTargeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid TumorsLinearly Patterned Programmed Cell Necrosis Induced by Chronic Hypoxia Plays a Role in Melanoma Angiogenesis.3D Cell Culture in a Self-Assembled Nanofiber EnvironmentA novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosisIntegrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategiesMotility is critical for effective distribution and accumulation of bacteria in tumor tissueSingle-cell analysis demonstrates how nutrient deprivation creates apoptotic and quiescent cell populations in tumor cylindroids.Engineered bacteria detect spatial profiles in glucose concentration within solid tumor cell masses.Gold nanoparticles: opportunities and challenges in nanomedicine.Recent advances in drug delivery strategies for treatment of ovarian cancer.Nanopreparations to overcome multidrug resistance in cancer.Acidic tumor microenvironment in human melanoma.Micrometer-scale oxygen delivery rearranges cells and prevents necrosis in tumor tissue in vitro.Evaluation of biosafety and intracellular uptake of Cremophor EL free paclitaxel elastic liposomal formulation.Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.Mechanistic Model for Cancer Growth and Response to Chemotherapy.Surface PEGylation of Mesoporous Silica Nanorods (MSNR): Effect on loading, release, and delivery of mitoxantrone in hypoxic cancer cells.Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison.Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts.Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.Citrate inhibition of cisplatin reaction with DNA studied using fluorescently labeled oligonucleotides: implication for selectivity towards guanine.Intermittent chemotherapy is a treatment choice for advanced urothelial cancer.(99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.Biocompatibility and therapeutic evaluation of magnetic liposomes designed for self-controlled cancer hyperthermia and chemotherapy.Pelvic malignancy: integrating form and function.
P2860
Q24805788-C83AA819-D612-4346-BB50-35DC95C47578Q28550211-A94E43B8-B89F-47D4-9E13-DA5568C9D711Q28555006-00468A2B-FFF2-48B9-A31E-AB66EE9820EAQ30436995-13201653-3030-4128-AE7E-24AA0588A446Q30442799-47F879D9-BF18-4D07-93AC-5A85BE38B9D7Q30596704-D66A1FBA-1379-4D9F-A67D-FC1BDF3EDD3CQ33690336-15085FF4-B783-42B2-9605-82148D7EAA6FQ33756489-86530B35-99EE-4E1C-BAD8-A29627726CBAQ33792264-099DCA67-53FA-4502-BCA2-1605B00F843BQ34028584-389872BF-8A40-4B97-87B3-35D1132BE85DQ34182760-7391824B-E9DF-4B21-8DAD-CDB0CCFFF30AQ34190733-DF560A12-92A0-41C3-9CA0-FF5E4828E9BDQ34686233-E7FDE83A-0C95-4FFC-81EC-C7697D142607Q35074580-E9C0BF36-622F-41DC-B7B2-F0858D373BB8Q35845149-6BF9AC59-8E9D-4404-9B4E-AB881C7A1ECCQ35882977-1621A2C1-6A01-46AE-A38C-23816C56DFDEQ36134636-51B48A33-E804-40C6-A104-692BBCFF6B16Q36646199-A0666D10-50C0-4869-B4F2-768AF4CC1C37Q36840074-CD0BA694-8A19-4035-BE3F-01EE8011D234Q37115798-34EE9D23-5C5A-41AF-AEF4-A0C742BCFECCQ37165395-24300D65-2625-4E85-8648-15A85B76B350Q37284384-BF987A4D-AF9B-4A5E-9C86-71A77C07AA21Q37735165-FD843E8B-B418-497B-8870-506BB055E7ADQ37997512-C16B6084-A5E0-46E8-9E44-146523A044CEQ38131264-59B07218-5D80-4359-97B1-C9293D5D1817Q38846154-AB3DEB33-B71E-4370-A43B-848BAE341554Q39415390-D1B236AA-E649-4EB4-8793-4B4386C201FBQ39445090-E6268FCB-5554-4D2D-802B-2DC9B3EA2A79Q40424631-376E1C41-6D12-49B7-AB0C-4E6E3CF1C9B5Q41449440-51FF8E55-5A16-4587-881A-5FC7B7AADF28Q41963396-F7119C07-3487-48F0-A270-EFEF719F8915Q42140230-7AB5BF8C-78C6-4728-9233-538179D95D99Q42497866-5BBEFB16-A05E-493E-BA30-CF653D95A631Q44038782-54BD44A2-9510-4710-A93E-255AEC86CF44Q45361492-57C17AF4-F81F-4A12-840D-DF2F246CDE7FQ48425351-E8D63BC6-F804-4044-AB74-3F702E8D3BFCQ52948537-68BC2AEA-8B2A-4A12-B5D4-621A43373E84Q53287849-F7AFA89D-AC4B-4399-9793-8BE2F7CC2705Q53562438-B89FC632-49F6-4A01-8953-C4A953E903DF
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Tumor physiology and drug resistance.
@ast
Tumor physiology and drug resistance.
@en
Tumor physiology and drug resistance.
@nl
type
label
Tumor physiology and drug resistance.
@ast
Tumor physiology and drug resistance.
@en
Tumor physiology and drug resistance.
@nl
prefLabel
Tumor physiology and drug resistance.
@ast
Tumor physiology and drug resistance.
@en
Tumor physiology and drug resistance.
@nl
P356
P1476
Tumor physiology and drug resistance.
@en
P2093
Tannock IF
P2888
P304
P356
10.1023/A:1013125027697
P577
2001-01-01T00:00:00Z
P6179
1020855156